Covid-19 vaccines, lockdowns and equities
Insights

Covid-19 vaccines, lockdowns and equities

With the Covid-19 case count rising rapidly across the United States and Europe, the immediate economic outlook associated with renewed lockdowns is turning darker. But announcements from Pfizer and Moderna around the efficacy of their vaccines has cheered financial markets considerably. So how do we approach the possible short-term deterioration in economic data with the greater certainty about the longer-term path to normalisation?

Better-than-expected vaccine results drive markets higher

Our expectation, and the expectation of many forecasters, had been for vaccine candidates to report decent rather than spectacular efficacies, and for vaccines to begin to be deployed towards the end of 2020. As such the recent news has been a positive surprise when compared to the base case. Furthermore, the tail-risk of no immediately successful vaccine has in the past week been summarily dismissed, and the associated implications for markets have been profound. Firms which were uninvestable without the prospect of a successful vaccine have become once more subject to analytical scrutiny. As such the significant advance and rotation in equity markets makes sense:
  • The firms most profoundly impacted by Covid-19, such as travel and leisure firms, have jumped enormously in value over recent days as they have become investable again
  • Firms that we would anticipate performing well under a reflationary environment have also risen impressively, although not to the same extent
  • Good-quality firms that will prosper under most scenarios (except one without a successful vaccine) have also performed well as the left-tail scenario has been cut.

Considering the longer-term impacts of Covid-19

However, the pandemic crisis has left a profound impact on the economy and on financial markets. Without the novel coronavirus we wouldn’t have had the deep and sudden weakening of the real economy that has given large public companies the opportunity to accelerate their disruption of “old economy” sectors. Time will tell the degree to which anti-trust or regulatory responses will slow or reverse this latest land grab.
Without the crisis we wouldn’t have seen long-dated bond yields plummet (and with them discount rates used to value risky assets), pushing up the present value of future cash flows. The degree of economic scarring is still unknown, but most analysts, investors and indeed policymakers are betting that there will be no rapid rise in long-dated yields given the disinflationary impact that Covid-19 has ushered-in, most likely for the next couple of years.
And without Covid we wouldn’t have had a spike higher in levels of household, corporate and government debt. Higher levels of debt do not necessarily imply higher levels of debt service, given the collapse in bond yields, but they do place some limits on the degree to which rates can rise before monetary tightening is effected – meaning that equilibrium interest rates are, all else being equal, likely to be lower.

Summary

It may seem paradoxical that equity markets are rallying into a new economic slowdown, but it is worth recalling that large public companies are only a subset of the economy and that equities are long-duration assets. As such, the most important news we have received over recent days is that one possible future – that of no successful vaccine – no longer looks likely. And that is something that financial markets and humans alike can find common ground in cheering.
27 November 2020
Share article
Share on twitter
Share on linkedin
Share on email
Key topics
Related topics
Share article
Share on twitter
Share on linkedin
Share on email
Key topics
Related topics

PDF

Covid-19 vaccines, lockdowns and equities

Important Information

With the Covid-19 case count rising rapidly across the United States and Europe, the immediate economic outlook associated with renewed lockdowns is turning darker. But announcements around efficacy on new vaccines has cheered financial markets considerably. So how do we approach the possible short-term deterioration in economic data with the greater certainty about the longer-term path to normalisation?

Related Insights

23 September 2021

Credit Threads #2: Consumer balance sheets

In this episode of Credit Threads, we discuss the outlook for consumers and the ways bond investors can find opportunities in consumer debt.
Listen time - 24 min
20 September 2021

Mine Tzegul

Portfolio Manager

Process is everything for Pan European Smaller Companies

The onset of Covid-19 in Europe initially saw value and cyclical stocks perform poorly. But as the continent emerged out of the first wave towards the end of summer 2020, this began to reverse.
Read time - 5 min
20 September 2021

Paul Doyle

Head of Europe ex-UK Equities

Walking the delicate path to normalisation

In spite of summer jitters in financial markets, we expect governments will cautiously normalise monetary policy and global growth will remain robust. We believe there is further upside for equities, especially in cyclical sectors poised to gain from economic reopening.
Read time - 5 min

You may also like

Investment approach

Teamwork defines us and is fundamental to our investment approach, which is structured to facilitate the generation, assessment and implementation of good, strong investment ideas for our portfolios.

Funds and Prices

Columbia Threadneedle Investments has a comprehensive range of investment funds catering for a broad range of objectives.

Our Capabilities

We offer a broad range of actively managed investment strategies and solutions covering global, regional and domestic markets and asset classes.